Seminar
Since the publication of the addendum of the ICH E9(R1) guideline, estimands have received more attention.
The addendum is definitely a step in the right direction, as it emphasizes the importance of estimating an effect that answers
the clinical question of interest.
However, so far, relatively little attention has been paid to the practical implementability of estimands in clinical trials,
difficulties in doing so and concerns about the developments surrounding estimands.
This seminar will host four experts from academia and the pharmaceutical industry who will give introductions and
perspectives on the theme.
Moreover, the opportunities and potential of recently developed causal inference methods will be discussed
and illustrated using case studies.
Speakers
Mouna Akacha, Novartis
Jonathan Bartlett, London School of Hygiene & Tropical Medicine
Kelly Van Lancker, Ghent University
Stijn Vansteelandt (Discussant), Ghent University